Citadel Advisors’s Pharvaris PHVS Stock Holding History

Citadel Advisors’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.76M	Buy	168,630 +33,561	+25%	+$896K	﹤0.01%	4422
2025 Q4	$3.75M	Buy	135,069 +5,331	+4%	+$128K	﹤0.01%	4773
2025 Q3	$3.24M	Buy	129,738 +100,517	+344%	+$2.23M	﹤0.01%	5167
2025 Q2	$514K	Buy	+29,221	New	+$471K	﹤0.01%	8564
2024 Q3	–	Sell	-14,472	Closed	-$272K	–	14978
2024 Q2	$272K	Sell	14,472 -223,833	-94%	-$4.55M	﹤0.01%	9331
2024 Q1	$5.51M	Buy	238,305 +96,847	+68%	+$2.57M	﹤0.01%	3801
2023 Q4	$3.97M	Buy	+141,458	New	+$2.86M	﹤0.01%	4141

Other funds holding PHVS

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EFM

EQT Fund Management Luxembourg $1.02B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Citadel Advisors's PHVS Position: Q1 2026 in Review

Citadel Advisors increased its Pharvaris (PHVS) stake by 25% in Q1 2026, buying an estimated $896K and bringing the position to 168,630 shares worth $4.76M. The position accounts for ﹤0.01% of the portfolio, ranked #4422.

Citadel Advisors first reported a position in PHVS in Q4 2023 and has held it in 7 quarters since. The position peaked at $5.51M in Q1 2024. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

Citadel Advisors held 168,630 shares of Pharvaris worth $4.76M as of Q1 2026.
Citadel Advisors bought 33,561 Pharvaris shares in Q1 2026, an estimated $896K.
Pharvaris made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4422 holding.
Citadel Advisors first reported a position in Pharvaris in Q4 2023 and has held it in 7 quarters since.
Citadel Advisors's Pharvaris position peaked at $5.51M in Q1 2024.
110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.